| Literature DB >> 32714268 |
Ming-Qian Ou1,2, Wei-Hao Fan1,3, Fu-Rong Sun1,3, Wan-Xin Jie1, Mei-Jun Lin1, Yu-Jie Cai1,3, Shi-Yun Liang1, Yang-Sheng Yu4, Min-Hua Li1, Li-Li Cui1,3, Hai-Hong Zhou1,3.
Abstract
Background: Migraine is an intractable headache disorder, manifesting as periodic attacks. It is highly burdensome for patients and society. Acupuncture treatment can be beneficial as a supplementary and preventive therapy for migraine.Entities:
Keywords: acupuncture; efficacy and safety; meta-analysis; migraine; systematic review; transcranial doppler
Year: 2020 PMID: 32714268 PMCID: PMC7344239 DOI: 10.3389/fneur.2020.00596
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Figure 1The different phases of the search of the 8 databases and the selection of the studies included in the present analyses.
Characteristics of the included studies in the meta-analysis.
| Wu et al. ( | China | 40 vs. 40 vs. 0 | 0 | Acupuncture | Flunarizine | / | / | 1 month | FM, DM, VAS, ER | 1 month |
| Xiao et al. ( | China | 30 vs. 30 vs. 30 | 0 | Electro-acupuncture | Diclofenac sodium | Non-acupoint | / | 1 month | VAS, ER | 1 month |
| Tastan et al. ( | Turkey | 30 vs. 30 vs. 0 | 6 vs. 0 vs. 0 | Acupuncture | Acetaminophen | / | / | 1 month | VAS | 3 months |
| Wang et al. ( | China | 20 vs. 0 vs. 20 | 1 vs. 0 vs. 1 | Acupuncture | / | Non-acupoint | / | 1 month | FM, DM, VAS | 2 months |
| Shu et al. ( | China | 60 vs. 60 vs. 0 | 2 vs. 3 vs. 0 | Acupuncture | Flunarizine hydrochloride | / | / | 1 month | VAS, ER | 2 months |
| Zhang ( | China | 60 vs. 60 vs. 0 | 0 | Acupuncture | Nimodipine + Oryzanol | / | Before and after treatment | 1 month | TCD, VAS, ER | 1 month |
| Chen et al. ( | China | 38 vs. 0 vs. 38 | 0 | Acupuncture | / | Non-acupoint | / | 1 month | DM, ER, AE | 2 months |
| Ling et al. ( | China | 83 vs. 0 vs. 80 | 0 | Acupuncture | / | Non-acupoint | / | 1 month | FM, VAS | 2 months |
| Wei et al. ( | China | 30 vs. 30 vs. 0 | 0 | Acupuncture & blood-letting | Fenbid | / | / | 1 month | FM, DM | 1 month |
| Sun et al. ( | China | 30 vs. 30 vs. 0 | 0 | Acupuncture | Ergotamine | / | / | 1 month | VAS, ER | 1 month |
| Cai et al. ( | China | 20 vs. 0 vs. 20 | 1 vs. 0 vs. 1 | Acupuncture | / | Non-acupoint | / | 1 month | FM, DM, VAS, ER | 1 month |
| Su et al. ( | China | 35 vs. 32 vs. 0 | 0 | Acupuncture | Flunarizine hydrochloride | / | / | 1 month | FM, DM, VAS, ER | 1 month |
| Liu et al. ( | China | 58 vs. 58 vs. 0 | 0 | Electro-acupuncture | Nimodipine + aspirin | / | / | 1 month | FM, DM, ER | NA |
| Zhang et al. ( | China | 33 vs. 34 vs. 0 | 2 vs. 1 vs. 0 | Acupuncture | Flunarizine | / | Within 2 days before treatment and 2 days after treatment | 1 month | TCD,VAS, ER,AE | 1 month |
| Qu and Shen ( | China | 31 vs. 31 vs. 0 | 0 | Acupuncture | Flunarizine hydrochloride | / | / | 1 month | FM, VAS, AE | 1 month |
| Chen S ( | China | 38 vs. 36 vs. 37 | 1 vs. 2 vs. 2 | Acupuncture | Flunarizine hydrochloride | Non-acupoint | / | 1 month | FM, VAS, ER, AE | 2 months |
| Chen et al. ( | China | 70 vs. 0 vs. 70 | 0 | Acupuncture | / | Non-acupoint | / | 1 month | FM, VAS | 2 months |
| Zhang et al. ( | China | 37 vs. 38 vs. 38 | 0 vs. 3 vs. 2 | Acupuncture | Flunarizine hydrochloride | Non-acupoint | 4 weeks before treatment, 4 weeks after treatment and 8 weeks after treatment | 1 month | FM, DM, TCD, VAS, ER | 2 months |
| Yang et al. ( | China | 76 vs. 0 vs. 75 | 0 | Acupuncture | / | Non-acupoint | / | 1 month | FM, ER | NA |
| Cao et al. ( | China | 23 vs. 0 vs. 19 | 0 | Electro-acupuncture | / | Non-acupoint | / | 1 month | FM, VAS, ER | 6 months |
| Chen et al. ( | China | 30 vs. 0 vs. 29 | 0 | Acupuncture | / | Non-acupoint | / | 1 month | FM, DM, ER | 1 month |
| Foroughipour et al. ( | Iran | 50 vs. 0 vs. 50 | NA | Acupuncture | / | Non-acupoint | / | 1 month | FM | 4 months |
| Zheng et al. ( | China | 60 vs. 60 vs. 0 | 1 vs. 2 vs. 0 | Acupuncture | Flunarizine hydrochloride | / | Before and after treatment | 1 month | TCD, ER, AE | 1 month |
| Liu et al. ( | China | 42 vs. 42 vs. 0 | 0 | Acupuncture | Nimodipine + Ergotamine | / | Before and after treatment | 1 month | FM, DM, TCD, ER | 1 month |
| Ying L et al. ( | China | 108 vs. 0 vs. 107 | 0 | Acupuncture | / | Non-acupoint | / | 1 month | FM, VAS | 2 months |
| Wang et al. ( | China | 70 vs. 70 vs. 0 | 9 vs. 11 vs. 0 | Acupuncture | Flunarizine hydrochloride | / | / | 1 month | FM, VAS | 1 month |
| Zhong et al. ( | China | 114 vs. 104 vs. 0 | 0 | Acupuncture | Flunarizine hydrochloride | / | / | 1 month | FM, DM, ER | 1 month |
| Allais et al. ( | Italy | 80 vs. 80 vs. 0 | 3 vs. 7 vs. 0 | Acupuncture | Flunarizine hydrochloride | / | / | 2 months | FM, ER | 6 months |
AC vs. MD vs. SAC: acupuncture group vs. medication group vs. sham acupuncture group; NA, not reported; FM, frequency of migraine; DM, duration of migraine; TCD, transcranial doppler; VAS, visual analog scale; ER, effective rate; AE, adverse events.
Figure 2Bias risk summary map.
Figure 3Forest plots of frequency and duration of migraine after acupuncture treatment.
Figure 4Forest plots of TCD changes after acupuncture treatment.
Figure 5Forest plots of the visual analog scale score and effective rate after treatment.
Figure 6Forest plots of the adverse effects after treatment.